Catalog No.
DHC21301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Lymphocyte IgE receptor, C-type lectin domain family 4 member J, Low affinity immunoglobulin epsilon Fc receptor, CD23A, BLAST-2, Immunoglobulin E-binding factor, IGEBF, CD23, Fc-epsilon-RII, CLEC4J, FCE2, FCER2
Concentration
1.66 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06734
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IDEC-152, P5E8, CAS: 357613-86-6
Clone ID
Lumiliximab
Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects, PMID: 16210051
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia, PMID: 19843887
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines, PMID: 18032710
Anti-CD23, PMID: 16222084
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia, PMID: 25130401
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia, PMID: 17671129
Technology evaluation: lumiliximab, Biogen Idec, PMID: 15663332
Novel Drugs in Follicular Lymphoma, PMID: 27872741
Refractory chronic lymphocytic leukemia--new therapeutic strategies, PMID: 21317446
Treatment of relapsed or refractory chronic lymphocytic leukemia, PMID: 22143061
Monoclonal antibodies in chronic lymphocytic leukemia, PMID: 17020457
Antibody therapy for chronic lymphocytic leukemia, PMID: 18381104
Monoclonal antibody therapy of chronic lymphocytic leukemia, PMID: 16187090
Newer monoclonal antibodies for hematological malignancies, PMID: 18565392
State-of-the-art treatment of chronic lymphocytic leukemia, PMID: 20008230
Targeted therapy for chronic lymphocytic leukemia, PMID: 19343298
Standard of care and novel treatments for chronic lymphocytic leukemia, PMID: 20966144
Modern concepts in the treatment of chronic lymphocytic leukemia, PMID: 19843378
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia, PMID: 18336199
Gateways to clinical trials, PMID: 18985183
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art, PMID: 25249370
Novel antibodies in the treatment of non-Hodgkin's lymphoma, PMID: 19767657
Gateways to clinical trials, PMID: 21225019
Novel agents for the treatment of chronic lymphocytic leukemia, PMID: 21326166
The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia, PMID: 23667725
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia, PMID: 19562616
Current and emerging treatments for chronic lymphocytic leukaemia, PMID: 19911856
Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells, PMID: 21277901
Phase behavior of an intact monoclonal antibody, PMID: 17449660
For research use only. Not for human or drug use.
